Zhejiang University School of Medicine Second Affiliated Hospital Completes First DMR Mitral Valve Repair Using DragonFly™ System

Hangzhou, Aug. 14, 2020 /PRNewswire/ -- On August 11, 2020, Professor Wang Jian’an’s team at the Second Affiliated Hospital of Zhejiang University School of Medicine successfully performed a transfemoral mitral valve repair using the DragonFly™ transcatheter mitral valve clip system, developed by Valgen Medtech Co., Ltd., on an 83-year-old patient with severe mitral regurgitation (P1 segment prolapse) and high surgical risk. This case marks the second successful implantation of the DragonFly™ system at the hospital, following its first case on July 23.^TMDragonFly Completed After Transfemoral Mitral Valve Repair (FMR)^TMFirst Case of Degenerative Mitral Regurgitation (DMR) Repair Surgery. During the procedure, Professor Wang Jian’an’s team implanted two DragonFly™ valve clips. Immediately post-procedure, mitral regurgitation was significantly reduced (from grade 4+ preoperatively to grade 1+, with complete resolution of valve prolapse). Left atrial pressure decreased markedly, while the mean transvalvular gradient across the mitral valve remained unchanged at 4 mmHg, indicating no iatrogenic mitral stenosis. The patient’s clinical symptoms improved significantly, and he was able to ambulate independently on the second postoperative day. The success of this surgery marks another solid step forward for the Zhejiang University Second Affiliated Hospital team, under the leadership of Professor Wang Jian’an, in advancing independent innovation in the field of interventional mitral valve diagnosis and treatment.

Professor Wang Jian’an from the Second Affiliated Hospital of Zhejiang University School of Medicine stated postoperatively: Mitral regurgitation is the most common valvular heart disease, and the treatment of elderly high-risk patients with mitral regurgitation has always been a focus in the field of cardiovascular medicine.ofHotspots and Challenges. The DragonFly™ product, which utilizes a transfemoral venous transseptal approach, can be applied to treat both functional mitral regurgitation (FMR) and degenerative mitral regurgitation (DMR). Compared with prolapse in segment 2 of the mitral valve, prolapse in segments 1 and 3 involves more complex anatomy and presents greater therapeutic challenges. In this case, the patient’s mitral valve prolapse was located in the P1 segment, and excellent procedural outcomes were achieved following treatment with the DragonFly™ system. This demonstrates that edge-to-edge mitral valve repair is applicable to prolapse lesions across all anatomical segments of the mitral valve. We look forward to more patients benefiting from this technology in the future.

Valgen Medtech focuses on the research and development of treatment technologies for structural heart disease, particularly mitral and tricuspid valve-related interventions. It is the only company globally that possesses two mature transcatheter mitral valve repair technologies. The company’s product, MitralStitch^®DragonFly™ is a transcatheter edge-to-edge repair device for the mitral valve via the femoral vein, featuring technical specifications comparable to those of the fourth-generation Abbott MitraClip, the international benchmark. Its optimized delivery system also enables the device to be used for interventional treatment of the tricuspid valve. Other mitral and tricuspid valve-related devices from Valgen Medtech are currently under development. The company is committed to researching and developing multiple technologies for minimally invasive interventional treatment of mitral and tricuspid valves (Tool-Box Concept), striving to advance the field of structural heart disease therapy and bringing Chinese innovation to benefit the world.